Ting Peng-Sheng, Lin Wei-Ting, Huang Chiung-Kuei, Lin Hui-Yi, Tseng Tung-Sung, Chen Po-Hung
Division of Gastroenterology and Hepatology, Tulane University School of Medicine, New Orleans, Louisiana, USA.
Social, Behavioral, and Population Sciences, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA.
Alcohol Clin Exp Res (Hoboken). 2024 Jan;48(1):88-97. doi: 10.1111/acer.15220. Epub 2023 Nov 29.
Metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol consumption have both increased in recent years, and there is debate as to whether nonheavy alcohol use is safe in MASLD. We analyzed the association between different nonheavy alcohol use patterns and at-risk liver fibrosis among individuals with MASLD.
We conducted a cross-sectional study of 1072 eligible National Health and Nutrition Examination Survey participants with MASLD who reported nonheavy alcohol consumption. We used vibration-controlled transient elastography to define the primary outcome of at-risk liver fibrosis as >8.2 kPa (stage F2-F4). Multivariable logistic regression models were used to determine the association of different alcohol consumption patterns (average drinks/day, drinking days/week, weekly alcohol intake, type of alcoholic beverage) and at-risk hepatic fibrosis, controlling for demographic/socioeconomic, lifestyle/dietary, and metabolic risk factors.
Exclusive liquor or cocktail drinkers had a 5.02-fold odds of at-risk fibrosis (95% CI: 1.15-21.95) compared with non-drinkers when controlling for potential confounders. While consuming an average of 2 drinks/day, ≥3 drinking days/week, or 1-3 drinks/week appeared to have a lower association with at-risk fibrosis when controlling for demographic/socioeconomic risk factors, the association was not present after controlling for lifestyle/dietary and metabolic risk factors.
There is an association between exclusive liquor/cocktail consumption and at-risk liver fibrosis in patients with MASLD who report nonheavy alcohol consumption.
近年来，代谢功能障碍相关脂肪性肝病（MASLD）和酒精消费均有所增加，对于非重度饮酒在MASLD中是否安全存在争议。我们分析了MASLD患者中不同非重度饮酒模式与肝纤维化风险之间的关联。
我们对1072名符合条件的美国国家健康与营养检查调查参与者进行了横断面研究，这些参与者患有MASLD且报告有非重度饮酒情况。我们使用振动控制瞬时弹性成像将肝纤维化风险的主要结局定义为>8.2 kPa（F2 - F4期）。多变量逻辑回归模型用于确定不同饮酒模式（平均每日饮酒量、每周饮酒天数、每周酒精摄入量、酒精饮料类型）与肝纤维化风险之间的关联，并对人口统计学/社会经济、生活方式/饮食和代谢风险因素进行控制。
在控制潜在混杂因素后，与不饮酒者相比，只饮用烈酒或鸡尾酒的人发生肝纤维化风险的几率高5.02倍（95%置信区间：1.15 - 21.95）。虽然在控制人口统计学/社会经济风险因素时，平均每天饮用2杯、每周饮酒≥3天或每周饮用1 - 3杯似乎与肝纤维化风险的关联较低，但在控制生活方式/饮食和代谢风险因素后，这种关联并不存在。
在报告有非重度饮酒的MASLD患者中，只饮用烈酒/鸡尾酒与肝纤维化风险之间存在关联。
